Monopar Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | — | $2.8M | $2.8M |
| FY2016 | — | $2.8M | $2.1M |
| FY2017 | — | $9.6M | $9.0M |
| FY2018 | — | $6.9M | $6.9M |
| FY2019 | — | $12.6M | $13.2M |
| FY2020 | — | $15.7M | $16.7M |
| FY2021 | — | $18.9M | $20.3M |
| FY2022 | — | $10.1M | $8.2M |
| FY2023 | — | $5.6M | $7.3M |
| FY2024 | — | $55.0M | $45.8M |